Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Haematologica. 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15.

¹ Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France.
² Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁴ Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA.
⁵ Department of Internal Medicine III, University Hospital of Ulm, Germany.
⁶ Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
⁷ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
⁸ Department of Hematology, Jagiellonian University, Krakow, Poland.
⁹ Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA.
¹⁰ Department of Medicine, Oncology Division, Washington University School of Medicine, St Louis, MO, USA.
¹¹ Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA.
¹² Gilead Sciences Inc., Foster City, CA, USA.
¹³ At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA.
¹⁴ Institute of Hematology and Oncology, University of Bologna, Italy.
¹⁵ Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA agopal@u.washington.edu.

No abstract available

Publication types